Synthetic Antiangiogenic Vascular Endothelial Growth Factor—A Splice Variant Revascularizes Ischemic Muscle in Peripheral Artery Disease
Journal of the American Heart Association · 2024
DOI: 10.1161/jaha.124.034304 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of the American Heart Association, 2024. Verfasst von Adarshini Raja und 1 weiteren Autor:innen. Beteiligte Einrichtung: Medical College of Georgia Augusta University Augusta GA USA. Hauptthemen laut MEDLINE: Peripheral Arterial Disease, Vascular Endothelial Growth Factor A, Ischemia, Vascular Endothelial Growth Factor Receptor-2. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS.
Abstract (Originalsprache)
Background
Alternative splicing in the eighth exon C‐terminus of VEGF‐A (vascular endothelial growth factor‐A) results in the formation of proangiogenic VEGF 165 a and antiangiogenic VEGF 165 b isoforms. The only known difference between these 2 isoform families is a 6‐amino acid switch from CDKPRR (in VEGF 165 a) to SLTRKD (in VEGF 165 b). We have recently shown that VEGF 165 b can induce VEGFR2‐activation but fails to induce VEGFR1 (VEGF receptor 1)‐activation. The molecular mechanisms that regulate VEGF 165 b's ability toward differential VEGFR2 versus VEGFR1 activation/inhibition are not yet clear. Methods and Results Hypoxia serum starvation was used as an in vitro peripheral artery disease model. Unilateral single ligation of the femoral artery was used as a preclinical peripheral artery disease model. VEGFR1 activating ligands have 2 arginine (RR) residues in their eighth exon C‐terminus, that were replaced by lysine‐aspartic acid (KD) in VEGF 165 b. A synthetic anti‐angiogenic VEGF 165 b splice variant in which the KD residues were switched to RR (VEGF 165 b KD→RR ) activated both VEGFR1‐ and VEGFR2‐signaling pathways to induce ischemic‐endothelial cell angiogenic capacity in vitro and enhance perfusion recovery in a severe experimental‐peripheral artery disease model significantly higher than VEGF 165 a. Phosphoproteome arrays showed that the therapeutic efficacy of VEGF 165 b KD→RR over VEGF 165 a is due to its ability to induce P38‐activation in ischemic endothelial cells.
Conclusions
Our data shows that the KD residues regulate VEGF 165 b's VEGFR1 inhibitory property but not VEGFR2. Switching these KD residues to RR resulted in the formation of a synthetic/recombinant VEGF 165 b KD→RR isoform that has the ability to activate both VEGFR1‐ and VEGFR2‐signaling and induce ischemic‐endothelial cell angiogenic and proliferative capacity that matched the angiogenic requirement necessary to achieve perfusion recovery in a severe experimental‐peripheral artery disease model.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Medical College of Georgia Augusta University Augusta GA USA.
- Vascular Biology Center and Department of Medicine Augusta University Augusta GA USA.
ORCID-Profile: Vijay Ganta
Förderung
- NHLBI NIH HHS
Zitieren
APA
Raja, A., & Ganta, V. (2024). Synthetic Antiangiogenic Vascular Endothelial Growth Factor—A Splice Variant Revascularizes Ischemic Muscle in Peripheral Artery Disease. Journal of the American Heart Association. https://doi.org/10.1161/jaha.124.034304
Vancouver
Raja A, Ganta V. Synthetic Antiangiogenic Vascular Endothelial Growth Factor—A Splice Variant Revascularizes Ischemic Muscle in Peripheral Artery Disease. Journal of the American Heart Association. 2024. doi:10.1161/jaha.124.034304
BibTeX
@article{Raja2024,
author = {Raja, Adarshini and Ganta, Vijay},
title = {Synthetic Antiangiogenic Vascular Endothelial Growth Factor—A Splice Variant Revascularizes Ischemic Muscle in Peripheral Artery Disease},
journal = {Journal of the American Heart Association},
year = {2024},
doi = {10.1161/jaha.124.034304}
}
EUVIMED